​

Cytokinetics Ownership | Who Owns Cytokinetics?


OverviewForecastRevenueFinancialsChartTranscripts

Cytokinetics Ownership Summary


Cytokinetics is owned by 131.25% institutional investors, 0.65% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 15.93% of CYTK shares. T. Rowe Price Capital Appreciation is the top mutual fund, with 4.52% of its assets in Cytokinetics shares.

CYTK Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCytokinetics131.25%0.65%-31.90%
SectorHealthcare Stocks 247.07%12.15%-159.22%
IndustryBiotech Stocks 385.89%11.79%-297.68%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de21.04M15.93%$1.39B
T. rowe price investment management18.72M15.18%$1.59B
Blackrock14.67M14.40%$794.97M
Vanguard group12.05M10.04%$765.54M
Wellington management group llp6.93M5.62%$590.52M
State street7.14M5.41%$470.81M
Vanguard portfolio management6.80M5.15%$448.16M
Vanguard capital management6.27M4.74%$413.02M
Avoro capital advisors5.00M4.06%$425.95M
Bank of america corp /de/4.64M3.76%$394.92M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Royalty pharma sub-manager980.39K32.92%$64.62M
Rp management980.39K22.73%$51.76M
Foresite capital management iv714.70K20.98%$60.88M
Sarissa capital management lp228.62K10.95%$19.48M
Checkpoint capital517.28K7.71%$34.09M
Melqart asset management (uk)767.52K6.22%$65.39M
Boxer capital2.10M5.99%$113.78M
Integral health asset management1.60M5.38%$136.30M
First turn management527.41K4.81%$44.93M
Gsk340.43K4.51%$22.44M

Top Buyers

HolderShares% AssetsChange
Blackrock14.67M0.02%2.26M
Invesco3.02M0.02%1.78M
Avoro capital advisors5.00M3.82%1.67M
Bank of america corp /de/4.64M0.03%1.51M
T. rowe price investment management18.72M1.05%1.19M

Top Sellers

HolderShares% AssetsChange
Darwin global management---4.58M
Fmr2.23M0.01%-2.81M
Sixth street partners management company---1.57M
Paradigm biocapital advisors lp---1.48M
Westfield capital management co lp---1.31M

New Positions

HolderShares% AssetsChangeValue
Holocene advisors, lp1.14M0.22%1.14M$97.51M
Norges bank1.02M0.01%1.02M$86.51M
Wcm investment management910.49K0.10%910.49K$59.76M
Vaughan nelson investment management661.16K0.45%661.16K$43.58M
Jump financial220.85K0.10%220.85K$14.56M

Sold Out

HolderChange
Stone house investment management-1.00
New england capital financial advisors-1.00
Plante moran financial advisors-1.00
Financial gravity asset management-2.00
Strategic advocates-2.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20265073.05%161,798,31610.76%1310.92%33328.57%103-26.43%
Mar 31, 2026258-45.45%51,788,965-62.86%430.32%147-42.35%69-46.92%
Dec 31, 2025328-22.64%72,535,010-48.66%600.43%182-19.82%87-18.69%
Sep 30, 202540316.47%144,458,2314.66%1200.91%21725.43%105-0.94%
Jun 30, 2025344-10.88%137,969,5181.88%1150.88%171-14.50%106-0.93%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
T. Rowe Price Capital Appreciation6.29M4.52%-
Vanguard Health Care Inv5.69M4.09%2.58M
iShares Core S&P Mid-Cap ETF5.00M3.59%2.68K
Vanguard MStar Total Stk Mkt Idx Invest4.45M3.20%124.03K
Vanguard Total Stock Mkt Idx Inv4.32M3.18%30.41K
Vanguard Morn Total Stk Mkt Idx Investor4.32M3.18%30.41K
Vanguard US Total Market Shares ETF3.75M3.15%128.42K
iShares Russell 2000 ETF3.42M2.46%-
Vanguard Small Cap Index3.13M2.25%5.32K
American Funds SMALLCAP World A2.62M1.89%-372.10K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 09, 2026PARSHALL B LYNNE-Sell$141.19K
Nov 09, 2026PARSHALL B LYNNE-Sell$132.45K
Nov 03, 2026Malik Fady Ibraham EVP Research & DevelopmentSell$220.25K
Nov 02, 2026Blum Robert I President & CEOSell$471.07K
Oct 20, 2026Malik Fady Ibraham EVP Research & DevelopmentSell$224.03K

Insider Transactions Trends


DateBuySell
2026 Q4-5
2026 Q3-20
2026 Q2-25
2026 Q1-22
2025 Q4-20

CYTK Ownership FAQ


Who Owns Cytokinetics?

Cytokinetics shareholders are primarily institutional investors at 131.25%, followed by 0.65% insiders and -31.90% retail investors. The average institutional ownership in Cytokinetics's industry, Biotech Stocks , is 385.89%, which Cytokinetics falls below.

Who owns the most shares of Cytokinetics?

Cytokinetics’s largest shareholders are Blackrock funding, inc. /de (21.04M shares, 15.93%), T. rowe price investment management (18.72M shares, 15.18%), and Blackrock (14.67M shares, 14.40%). Together, they hold 45.51% of Cytokinetics’s total shares outstanding.

Does Blackrock own Cytokinetics?

Yes, BlackRock owns 14.40% of Cytokinetics, totaling 14.67M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 794.97M$. In the last quarter, BlackRock increased its holdings by 2.26M shares, a 18.19% change.

Who is Cytokinetics’s biggest shareholder by percentage of total assets invested?

Royalty pharma sub-manager is Cytokinetics’s biggest shareholder by percentage of total assets invested, with 32.92% of its assets in 980.39K Cytokinetics shares, valued at 64.62M$.

Who is the top mutual fund holder of Cytokinetics shares?

T. Rowe Price Capital Appreciation is the top mutual fund holder of Cytokinetics shares, with 4.52% of its total shares outstanding invested in 6.29M Cytokinetics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools